Cargando…
Feasibility of Integrating Panel-Based Pharmacogenomics Testing for Chemotherapy and Supportive Care in Patients With Colorectal Cancer
INTRODUCTION: Pharmacogenomics is about selecting the “right drug in the right amount for the right patient.” In metastatic colorectal cancer, germline pharmacogenomics testing presents a unique opportunity to improve outcomes, since the genes dihydropyrimidine dehydrogenase and UDP-glucuronosyltran...
Autores principales: | Kasi, Pashtoon Murtaza, Koep, Tyler, Schnettler, Erica, Shahjehan, Faisal, Kamatham, Vaishnavi, Baldeo, Candice, Hughes, Caren L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753511/ https://www.ncbi.nlm.nih.gov/pubmed/31533552 http://dx.doi.org/10.1177/1533033819873924 |
Ejemplares similares
-
Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
por: Shahjehan, Faisal, et al.
Publicado: (2019) -
Role of Circulating Tumor DNA in Gastrointestinal Cancers: Update From Abstracts and Sessions at ASCO 2018
por: Shahjehan, Faisal, et al.
Publicado: (2019) -
Circulating Tumor DNA-Based Detection of Microsatellite Instability and Response to Immunotherapy in Pancreatic Cancer
por: Kamatham, Saivaishnavi, et al.
Publicado: (2020) -
Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
por: Baldeo, Candice, et al.
Publicado: (2018) -
Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma
por: Yarlagadda, Bhavya, et al.
Publicado: (2019)